Summary
The pharmacokinetics of sulphinpyrazone and its major metabolites (sulfide, sulfone, p-hydroxysulfone and p-hydroxy-sulphinpyrazone) were investigated in 9 volunteers after a single oral dose as well as after chronic treatment for 23 days. Chronic administration of sulphinpyrazone, in comparison with a single oral dose, led to significant changes in plasma AUC (115.86 to 42.90 mg/l·h), in renal clearance (1.06 to 1.80l/h), in hepatic intrinsic clearance (319.0 to 598.0l/h), and in the unbound fraction in plasma 1.15 to 1.69%) and in tissue (2.73 to 1.31%). The volume of distribution changed from 20.24 to 52.041. The steady state concentrations predicted from the single dose were significantly higher than the values found after chronic treatment. The results suggest that sulphinpyrazone induces its own metabolism. The metabolism of the sulfone, p-hydroxysulfone and the p-hydroxy-sulphinpyrazone to further degradation products was also induced. Chronic treatment with sulphinpyrazone reduced the plasma AUC of the sulfide and caused a decrease in its elimination half-life (20.9 to 14.3 h). Since considerable amounts of the sulfide are formed in the G.I. tract, it is suggested that besides the induction of metabolism, bacteria which reduce sulphinpyrazone to the sulfide may also be responsible for the observed pharmacokinetic changes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aldridge A, Johnson GE (1972) Excretion of sulfinpyrazone in the rat. Can J Physiol Pharmacol 50: 1061–1065
Benet LZ, Galeazzi RL (1979) Noncompartimental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074
Boxenbaum HG, Bekersky I, Jack ML, Kaplan SA (1979) Influence of gut microflora on bioavailability Drug Metab Rev 9: 259–279
Bradbrook ID, John VA, Morrison PJ, Rogers HJ, Spector RG (1982) Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. Br J Clin Pharmacol 13: 177–185
Brodie BB, YU TF, Burns JJ, Chenkin T, Paton BC, Steele JM, Gutman AB (1954) Observations on G-25671 a phenylbutazone analogue (4-(phenylthioethyl)-1.2-diphenyl-3.5-pyrazolidine-dione). Proc Soc Exp Biol Med 86: 884–894
de Vries JX, Staiger Ch, Wang NS, Schlicht F (1983) Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr 277: 408–413
Dieterle W, Faigle JW, Moppert J (1980) New metabolites of sulfinpyrazone in man. Arzneimforsch 30: 989–993
Dieterle W, Faigle JW (1981) Species differences in the disposition and metabolism of sulfinpyrazone. Xenobiotica 11: 559–568
George CF, Oates J, Sembi J, Strang A, Renwick AG (1983) Sulphinpyrazone metabolism in the gut: effects of disease and concurrent drug therapy. II World Conference on Clinical Pharmacology and Therapeutics: Washington DC, July 31–August 5, 1983 (Abstract No. 798)
Gibaldi M, McNamara PJ (1977) Tissue binding of drugs. J Pharm Sci 66: 1211–1212
Gibaldi M, Levy G, McNamara PJ (1978) Effect of plasma protein and tissue binding on the biologic half-live of drugs. A commentary. Clin Pharmacol Ther 24: 1–4
Godbillon J, Gauron S, Gosset G (1982) High-performance liquid chromatographic analysis of the sulfide metabolite of sulfinpyrazone in plasma. J Chromatogr 227: 516–520
Houston JB (1982) Drug metabolite kinetics. Pharmacol Ther 15: 521–552
Jakobsen P, Kirstein Pedersen A (1981b) Simulaneous determination of sulfinpyrazone and four of its metabolites by high-performance liquid chromatography. J Chromatogr 223: 460–465
Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M (1974) Arteriovenous shunt thrombosis prevention by sulfinpyrazone. N Engl J Med 290: 304–306
Kirstein Pedersen A, Jakobsen P (1979) Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of prolonged in vivo effect. Thromb Res 16: 871–876
Lecaillon JB, Sopupart C, Schoeller JP, Humbert G, Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther 26: 611–617
Maguire ED, Pay GF, Wallis RB, White AM (1981b) Prolonged inhibition of ex vivo sodium arachidonate induced platelet aggregation and malondialdehyde production by sulfinpyrazone in man. Thromb Res 21: 321–327
Mahony C, Wolfram KM, Nash PV, Bjornsson PD (1983) Kinetics and metabolism of sulphinpyrazone. Clin Pharmacol Ther 33 (4): 491–497
Pang KS, Rowland M, Tozer TN (1978) In vivo evaluation of Michaelis-Menten constants of hepatic drug eliminating systems: a commentary. Drug Metab Dispos 6: 197–200
Renwick AG, Evans SP, Sweatman TW, Cumberland J, George LF (1982) The role of the gut flora in the reduction of sulphinpyrazone in the rat. Biochem Pharmacol 31: 2649–2656
Rosenkranz B, Fischer C, Jakobsen P, Kirstein Pedersen A, Fröhlich JC (1983) Plasma levels of sulfinpyrazone and two of its metabolites after a single dose and during steady-state. Eur J Clin Pharmacol 24: 231–235
Staiger C, Schlicht F, de Vries JX, Gundert-Remy U, Wang NS, Walter E, Weber E (1984) Bioavailability of sulfinpyrazone and the formation of its sulfide metabolite after oral and intravenous administration Submitted for publication
Staiger C, Schlicht F, Walter E, Gundert-Remy U, Hildebrandt R, de Vries J, Wang NJ, Harenberg J, Weber E (1983) Effect of single and multiple doses of sulphinpyrazone and antipyrine metabolism and urinary excretion of 6-β-hydroxycartisol. Eur J Clin Pharmacol 25: 797–801
Steele PP, Carroll J, Overfield D, Genton E (1977) Effect of sulfinpyrazone on platelet survival time in patients with transient ischemic attacks. Stroke 8: 396–398
The Anturane Reinfarction Trial Research Group (1978) Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the anturane reinfarction trial. N Engl J Med 298: 289–295
Walter E, Staiger C, de Vries J, Zimmermann R, Weber E (1981) Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol 19: 353–358
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance: commentary. Clin Pharmacol Ther 18: 377–390
Yamaoka K, Nakagawa T, Una T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558
Author information
Authors and Affiliations
Additional information
In memory of Dr. Erhard Walter
Rights and permissions
About this article
Cite this article
Schlicht, F., Staiger, C., de Vries, J. et al. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. Eur J Clin Pharmacol 28, 97–103 (1985). https://doi.org/10.1007/BF00635715
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635715